The AeroImmune Pipeline
Pre-clinical
Phase I
Phase II
Phase III
NEW ARRIVALS
25% OFF
Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2
March 3, 2022
In: Cell
July 2, 2025
Induction of lung mucosal immunity by a next-generation inhaled aerosol COVID-19 vaccine: an open-label, multi-arm phase 1 clinical trial
In: Nature Communications
Pre-clinical
Phase I
Phase II
Phase III
NEW ARRIVALS
25% OFF
A Human Type 5 Adenovirus–Based Tuberculosis Vaccine Induces Robust T Cell Responses in Humans Despite Preexisting Anti-Adenovirus Immunity
October 2, 2013
In: Science Translational Medicine
January 6, 2022
Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans
In: JCI Insight
Pre-clinical
Phase I
Phase II
Phase III
REVOLUTIONIZING FLU VACCINES
Avian Influenza Virus Vaccine
The ongoing outbreak of H5N1 viruses has decimated wild animal populations, and forms an unprecedented threat to humans. This vaccine incorporates multiple bird flu antigens to protect against future zoonotic disease.
Pre-clinical
Phase I
Phase III
Phase II
TOWARDS UNIVERSAL FLU IMMUNITY
Universal Influenza Virus Vaccine
Seasonal influenza virus vaccines can vary in efficacy from year to year. Our approach will enhance the existing immune responses that humans have against influenza from previous vaccination and infection to broaden the scope of protection.
Pre-clinical
Phase I
Phase II
Phase III
NEW ARRIVALS
25% OFF
NEXT-GENERATION TB VACCINE
Multivalent Chimpanzee Adenovirus Vectored Tuberculosis Vaccine Tri:ChAd
It presents multiple tuberculosis antigens to enhance immune defense.
Intranasal multivalent adenoviral-vectored vaccine protects against replicating and dormant M.tb in conventional and humanized mice
February 23, 2023
In: NPJ Vaccines